Featured News
COMPANY
Dr. Amrie Grammer of AMPEL BioSolutions joins host Rich Bendis on BioTalk
CLICK TO VIEW ARTICLE & WATCH VIDEO > AMPEL BioSolutions Co-Founder and COO/CSO, Dr. Amrie Grammer guests on BioTalk to discuss building the Company in Charlottesville, VA, her work and recognition at NIH, and being a leader from the southern part of the...
Cville Company Uses Genetics and Big Data to Find Better Medical Treatments
CLICK TO READ AND LISTEN TO ARTICLE > Getting approval for new drugs takes years and costs companies millions of dollars. What’s more, clinical trials sometimes fail, leaving firms with nothing to show. Now, however, a Virginia company is taking a different...
UVA Students & Alums Succeed at AMPEL
CLICK TO VIEW ALUMNI BIOS >
Q&A: UVA-Trained Biotech Leader Setting Her Sights on Lupus
CLICK TO READ ORIGINAL ARTICLE > by Fariss Samarrai, farisss@virginia.edu Lupus is a complex autoimmune disease that affects more than 1.4 million Americans. Its treatment in the United States alone costs about $7 billion per year. Despite this impact and cost, the...
Potential Employers Descend on Grounds During Annual Career Fair
CLICK TO VIEW ORIGINAL ARTICLE > by Caroline Newman, news@virginia.edu On Wednesday and Thursday, University of Virginia students donned their professional best and headed to Newcomb Hall for the annual Fall Job and Internship Fair, where they met with recruiters...
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee
Virginia Catalyst Awards $2 Million in Grants to Support Life Sciences in the Commonwealth. Four collaborative projects involving Virginia research universities and industry partners selected to address major unmet healthcare needs, drive job creation and capital formation in Virginia.
PLATFORM
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PRODUCTS
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ -- AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is...
Experimental Blood Test Could Improve Fibromyalgia Treatment
A small pilot study suggests an experimental blood test for fibromyalgia – called FibroGENE — could be used to determine which drug works best for each patient. Researchers at AMPEL BioSolutions and Duke University Medical Center found genetic biomarkers in the blood cells of 18 lupus patients with fibromyalgia-like symptoms.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans. The application of AMPEL’s genomic approach to fibromyalgia could also assist pharmaceutical companies in drug development and clinical trials.Â
Local company unveils blood test to find treatments for chronic pain
A medical discovery has been made in Charlottesville that may help people who experience chronic pain, fatigue and brain fog. “This is a big problem. This is a clinical problem that is not addressed. And it’s a problem that tends to discount patients,” said CEO and Chief Medical Officer Peter Lipsky.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
Working with colleagues at Duke University Medical Center, AMPEL found unique gene signatures that identified patients with Lupus who had prominent features of fibromyalgia. These signatures served as the basis of FibroGENE®, capable of identifying subjects with fibromyalgia with or without Lupus.
PARTNERS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.